Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis patients may benefit from common supplements, study finds

NCT ID NCT07303088

Disease control Sponsor: University of Sfax Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether taking L-carnitine or Coenzyme Q10 supplements could lower oxidative stress (a type of cell damage) in adults with end-stage kidney disease who are on regular hemodialysis. Fifty-two participants took one of the supplements or a placebo for 12 weeks, followed by a 12-week washout period. Researchers measured blood markers of oxidative stress before, after treatment, and after the washout to see if the supplements helped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

Jun 2024

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients on chronic hemodialysis for at least 6 months. * Age between 18 and 85 years old. * Chronic hemodialysis performed 3 times per week with high-flux dialyzers. * Adequate dialysis dose : PRU ≥ 65% and/or KT/V \> 1.1. * Satisfactory control of uremia. * Life expectancy greater than 1 year. Exclusion Criteria: * History of Poor medication adherence. * Severe intercurrent infection. * Severe hepatocellular insufficiency. * Major cardiovascular event within 3 months before the study. * Intake of antioxidants (except vitamin D2 and/or active vitamin D). * Intake of vitamins E, D3, or B9 → Washout period of at least 1 month. * Intake of L-car, other amino acids, or CoQ10 → Washout period of at least 6 months. * Withdrawal of consent. * Major digestive intolerance/adverse effect during the intervention. * Severe infection/major cardiovascular event during the study. * Patient refusal to continue the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage kidney disease (ESRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage kidney disease (ESRD) Hemodialysis Oxidative stress response

Contacts and locations

Locations

  • Social security fund polyclinic

    Sfax, Sfax Ville, 3080, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.